BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 25, 2015
View Archived Issues
Programmable probiotics as urinary diagnostic markers for liver metastases
Read More
Encouraging first-in-human data obtained with BI-836826 in CLL
Read More
Safety of tesevatinib assessed in a phase Ib trial
Read More
Allied-Bristol Life Sciences licenses intellectual property from Harvard
Read More
Vical releases topline data from phase I/II study of therapeutic genital herpes vaccine
Read More
Guselkumab and ustekinumab do not meet primary endpoint in rheumatoid arthritis trial
Read More
Gladius Pharmaceuticals raises funds to develop treatments for multidrug-resistant infections
Read More
First patient recruited in phase II study of preterm labor drug OBE-001
Read More
Soligenix collaborates with NORD and CLF on pivotal study of SGX-301 for CTCL
Read More
Group in Taiwan discloses B-Raf and C-RAF kinase inhibitors
Read More
Vertex Pharmaceuticals patents ATR kinase inhibitors
Read More
Boehringer Ingelheim patent describes kinase inhibitors
Read More
Pfizer opens enrollment in phase III trial of rivipansel in sickle cell disease
Read More
Potential new cancer treatments under study at Hangzhou Minsheng
Read More
Sanofi presents soluble epoxide hydrolase inhibitors
Read More
EMA grants orphan drug designation to AveXis' gene therapy treatment for SMA
Read More
CytoDyn to develop PRO-140 for GvHD
Read More
Biotest regains rights to tregalizumab after AbbVie opts out of agreement
Read More
ELND-005 does not meet primary endpoint in Alzheimer's disease trial
Read More
Vaccinex initiates phase II trial of VX-15/2503 in Huntington's disease
Read More
RaQualia regains dalbavancin rights in Japan
Read More
Agios initiates phase I trial of AG-881 in advanced solid tumors with IDH mutation
Read More
FDA clears IND for phase IIa study of T3D-959 in Alzheimer's disease
Read More